Abstract
Boron neutron capture therapy (BNCT) is a targeted radiation therapy that significantly increases the therapeutic ratio relative to conventional radiotherapeutic modalities. A boron -10(10B)-l led compound is administered that transports densely concentrations of 10B to the target tumor relative to surrounding normal tissues. Subsequently followed by irradiation with thermal neutrons or epithermal neutrons, the short ranges of the alpha and 7Li particles released from the 10B(n, alpha)7Li reaction are so short that if tumor cells accumulate the boron compound selectively, only tumor cells can be killed. As the effectiveness of BNCT in killing tumor cells relies on the number of 10B atoms delivered to tumor, and the subcellular distribution of 10B and the thermal neutron fluence at the site of the tumor, the pharmaceutical distribution in tumor cells greatly affects the performance of BNCT. Monte Carlo calculations of the energy depositions of short-range particles with high LET coming from 10B disintegration were performed. This simulation permits us to study the influence of the allocation of intracellular 10B in cytoplasm, or nucleoplasm, or on cell membranes, or on contiguous cells. We demonstrate here a Monte Carlo computer model incorporating the following elements:1. To simplify geometry of tumor cells, we assume all of the following tumor cells having a spherical geometry shape in this simulation. Then, using Monte Carlo computation corrects the pharmaceutical distribution in the spherical geometry shape cell model.2.Selective the dimensions in nucleus and in cell.3.Input the absorbed fractions of boron only in cytoplasm, or nucleoplasm, or on cell membranes, or on contiguous cells. We can obtain various GAF (geometric adjustment factor) causing from different portions (the localization of boron in cytoplasm, or nucleoplasm, or on cell membranes, or on contiguous cells ) . As to that, we would estimate how the pharmaceutical distribution affects the performance of BNCT.